Scientific articles and guides about Mounjaro, Zepbound and tirzepatide
Tirzepatide shows promise for weight loss and glycemic control, but adults over 60 face unique considerations around safety, dosing, and drug interactions. Here's what the research tells us.
Tirzepatide changes how your body handles alcohol. From heightened intoxication to hypoglycemia risk, here is what the pharmacology and available data actually show.
Tirzepatide is a powerful medication for weight loss, but clinical trials consistently show it works best when combined with diet, exercise, and professional support.
Eli Lilly's SURMOUNT-ORO trial evaluated tirzepatide in adults with obesity and psoriasis or psoriatic arthritis. Here is what the study measured and why it matters for people managing these conditions together.
Tirzepatide users started reporting something unexpected beyond weight loss — changes in mood, cravings, and compulsive behaviors. Here's what the evidence actually shows.
Exploring whether tirzepatide can be used safely without medical oversight, what the documented risks are, and why the distinction between supervised and unsupervised use matters for patient outcomes.
A practical guide to understanding how growing ANVISA approvals affect tirzepatide access, pricing, and your treatment options in Brazil.
The FDA updated tirzepatide labeling to warn about potential interactions with oral contraceptives. Here's what the science actually says, and what women on the drug should do now.
Tirzepatide isn't approved for type 1 diabetes. Here's what the science says about off-label use, DKA risks, and what endocrinologists actually recommend.
Millions of Brazilians with private health plans have been denied coverage for Mounjaro. A TJ/SP ruling may have shifted the legal landscape. Learn what it means for you.
Answer a few quick questions and get tailored guidance for your treatment.
or download the app
